Loading…
← CockpitCompetitor Analysis › 4549.T Eiken Chemical Co., Ltd.Open in the cockpit ↗

Eiken Chemical Co., Ltd.4549.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Specialties
Momentum weak 32
Mkt cap
$466M
US dollars, full cap
Free float
86%
of shares outstanding
$/day
$1.65M
20-day average traded
Fwd P/E
24.5×
forward earnings
ROIC−WACC
-1.6 pp
WACC 6.8%
Hurdle
n/a
no reverse DCF
Next earnings
72 days
29 Jan 2027
Close · JPY¥2,273
1D+1.5%
1W+4.2%
1M-8.6%
3M-0.6%
6M-20.1%
YTD-5.6%
1Y-4.7%
ATR %2.7%
52w lowhigh35.1% off high

What Eiken Chemical does

Employees: 696

Eiken Chemical at a glance

Size Eiken Chemical (4549.T) is a Japan Health Care company (Medical Specialties) with a market value of $466M, the 1108th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,273 on 18 Nov 2026.

Performance Over six months the shares fell 20.1%, against -15.2% for the median peer and -1.4% for the Japan market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue grew 3.9% over the last twelve months (peer median +1.9%); the operating margin is 6.5% (peer median 2.7%).

Valuation It trades at 24.5× forward earnings against a peer median of 21.1× (4th most expensive of 9).

Capital Return on invested capital runs 1.6 points below its cost of capital (6.8% WACC).

Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 874549.T 81
Six months, rebased to 100: Eiken Chemical against the median of its 20 peers (local-currency closes).

Eiken Chemical financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥42.9B¥41.9B¥40.5B¥40.1B¥43.3B
Revenue growth—+3%+1%-7%—
Gross profit¥15.9B¥16.2B¥16.5B¥16.7B¥20.5B
EBITDA¥5.39B¥5.46B¥5.55B¥5.71B¥9.58B
Net income¥1.85B¥3.71B¥2.23B¥2.63B¥5.74B
Free cash flown/a-¥1.81B¥812M¥1.77B¥4.35B
Capital expendituren/a¥5.86B¥5.38B¥2.15B¥3.29B
Total debt¥5.80B¥7.29B¥4.47B¥4.33B¥4.31B

Quarterly statements and history in the cockpit →

Eiken Chemical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%0%+20%MDXG603309300289468530ANGOCEVI300246002016603987301033688606002932CU6603520MEDX688026688580MOBI4549.T6-month return →1-month return →
Up and to the right = strong over both horizons. Eiken Chemical is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%10×20×30×603309CEVI301033688606603520MEDX6880266885804549.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Eiken Chemical is the large dot.

Eiken Chemical competitors and peer comparison

How Eiken Chemical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Eiken Chemical against its 20 peers (data as of 18 Nov 2026)
Measure4549.TPeer medianRank in peer set
1-month return-8.6%-4.7%6th lowest of 21
6-month return-20.1%-15.2%9th lowest of 21
Distance from 52-week high-35.1%-41.7%9th highest of 21
Revenue growth (TTM)+3.9%+1.9%10th highest of 20
Operating margin6.5%2.7%8th highest of 20
Forward P/E24.5×21.1×4th most expensive of 9
ROIC minus cost of capital-1.6 pp-2.2 pp8th highest of 18
EV / EBITDA12.5×n/a—
Net debt / EBITDA-1.3×-0.8×2nd least indebted of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Eiken Chemical 4549.TJapan$466M-20%+4%6%24.5×n/an/a
MiMedx MDXGUnited States$464M-16%-23%-8%n/a10.9%+11.0%
WELL LEAD MEDICAL 603309.SSChina$473M-22%+1%15%11.9×-5.9%+7.7%
Beijing Leadman Biochemistry 300289.SZChina$460M-9%+46%1%n/a36.0%-6.9%
PROTEINA 468530.KSSouth Korea$460M+5%-59%-1,178%n/an/an/a
AngioDynamics ANGOUnited States$476M-4%+8%-6%n/an/an/a
CellaVision CEVI.STSweden$477M+64%+2%23%32.6×7.1%+10.0%
Guangdong Biolight Meditech 300246.SZChina$478M-35%+7%-8%n/a55.3%-4.7%
Guangdong Shirongzhaoye 002016.SZChina$453M-26%-31%3%n/a21.5%-11.7%
Shanghai Kindly Enterprises Development 603987.SSChina$452M-12%0%10%n/a-1.0%-2.8%
Medprin Regenerative Medical Technologies 301033.SZChina$482M-14%+23%31%22.4×4.3%+24.4%
Hangzhou Alltest Biotech 688606.SSChina$484M-20%0%13%6.9×-6.5%-4.3%
Wuhan Easy Diagnosis Biomedicine 002932.SZChina$485M-14%-9%-51%n/an/an/a
Clarity Pharmaceuticals CU6.AXAustralia$444M-33%n/an/an/an/an/a
Zhejiang Starry Pharmaceutical 603520.SSChina$491M-44%+9%3%25.8×n/an/a
medmix MEDX.SWSwitzerland$494M+11%-7%6%19.4×4.5%+5.0%
Huaren Pharmaceutical 300110.SZChina$440M-16%-3%6%n/a5.8%+0.3%
Guangzhou Jet Bio-Filtration 688026.SSChina$436M+39%+5%11%35.7×20.6%+2.2%
Nanjing Vishee Medical Technology 688580.SSChina$499M-43%+7%24%19.7×20.1%+4.2%
Zhejiang Orient Gene Biotech 688298.SSChina$500M-27%+18%-60%n/an/an/a
Mobia Medical MOBIUnited States$434M+2%+105%-145%n/an/an/a

Questions

Which companies are Eiken Chemical's closest peers?
The cockpit's peer set: MiMedx (MDXG), WELL LEAD MEDICAL (603309.SS), Beijing Leadman Biochemistry (300289.SZ), PROTEINA (468530.KS), AngioDynamics (ANGO), CellaVision (CEVI.ST), Guangdong Biolight Meditech (300246.SZ), Guangdong Shirongzhaoye (002016.SZ).
Is Eiken Chemical expensive compared with its peers?
On forward p/e it trades at 24.5× against a peer median of 21.1×, 4th most expensive of 9 in its peer set.
How has Eiken Chemical stock performed?
Over six months to 18 Nov 2026 the shares returned -20.1% against -15.2% for the median peer; over one year -4.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.